title: Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual.
authors.forename: C D
authors.initials: CD
authors.lastname: Pilcher
authors.forename: J J
authors.initials: JJ
authors.lastname: Eron
authors.forename: L
authors.initials: L
authors.lastname: Ngo
authors.forename: A
authors.initials: A
authors.lastname: Dusek
authors.forename: P
authors.initials: P
authors.lastname: Sista
authors.forename: J
authors.initials: J
authors.lastname: Gleavy
authors.forename: D
authors.initials: D
authors.lastname: Brooks
authors.forename: T
authors.initials: T
authors.lastname: Venetta
authors.forename: E
authors.initials: E
authors.lastname: DiMassimo
authors.forename: S
authors.initials: S
authors.lastname: Hopkins
mesh_terms: D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015700:HIV Envelope Protein gp41 / Q000737:chemistry*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors; D006801:Humans; D008297:Male; D008875:Middle Aged; D019888:Nelfinavir; D019829:Nevirapine; D010455:Peptides / Q000737:chemistry* / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors; D019258:Saquinavir
chemical_list: D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D017320:HIV Protease Inhibitors; D010455:Peptides; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D019888:Nelfinavir; D019258:Saquinavir